Distributing a safe and effective COVID-19 vaccine may be even more challenging than developing it, which is why CU Boulder researchers and the CU spinoff VitriVax Inc. are so focused on finding a way to get vaccines to 7.8 billion people.
The researchers are focused on a vaccine-manufacturing platform technology that addresses the need for temperature-stable, single-dose formulations of novel COVID-19 vaccines at the scale required for large human clinical trials.
The research team is able to do so with funding, licensing and startup support from Venture Partners at CU Boulder, the university’s commercialization arm. They also received a grant from the Boettcher Foundation, which has awarded nearly $1 million to researchers from Colorado's top universities and hospitals to help combat the COVID-19 pandemic.
“It has to be a solution that is suitable for the entire world,” said project lead Theodore Randolph, Gillespie Professor in the Department of Chemical and Biological Engineering.